Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | microtubule-associated protein tau | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus multilocularis | microtubule associated protein 2 | Get druggable targets OG5_133504 | All targets in OG5_133504 |
Echinococcus granulosus | microtubule associated protein 2 | Get druggable targets OG5_133504 | All targets in OG5_133504 |
Schistosoma japonicum | ko:K04380 microtubule-associated protein tau, putative | Get druggable targets OG5_133504 | All targets in OG5_133504 |
Schistosoma mansoni | microtubule-associated protein tau | Get druggable targets OG5_133504 | All targets in OG5_133504 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0924 | 0.5047 | 0.8206 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.076 | 0.385 | 0.8781 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0924 | 0.5047 | 0.8206 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0757 | 0.383 | 1 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0757 | 0.383 | 0.5 |
Leishmania major | trypanothione reductase | 0.0757 | 0.383 | 1 |
Mycobacterium tuberculosis | Probable reductase | 0.0924 | 0.5047 | 0.8206 |
Echinococcus granulosus | microtubule associated protein 2 | 0.0833 | 0.4385 | 1 |
Plasmodium falciparum | thioredoxin reductase | 0.0757 | 0.383 | 1 |
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0924 | 0.5047 | 0.8206 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.1075 | 0.615 | 1 |
Schistosoma mansoni | microtubule-associated protein tau | 0.0833 | 0.4385 | 0.4385 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0757 | 0.383 | 1 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.1075 | 0.615 | 1 |
Plasmodium falciparum | glutathione reductase | 0.0757 | 0.383 | 1 |
Brugia malayi | Thioredoxin reductase | 0.0757 | 0.383 | 1 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.1075 | 0.615 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.076 | 0.385 | 0.8781 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.1075 | 0.615 | 1 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0924 | 0.5047 | 0.8206 |
Toxoplasma gondii | thioredoxin reductase | 0.0757 | 0.383 | 1 |
Plasmodium vivax | glutathione reductase, putative | 0.0757 | 0.383 | 1 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0924 | 0.5047 | 0.8206 |
Trypanosoma brucei | trypanothione reductase | 0.0757 | 0.383 | 1 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0757 | 0.383 | 0.6227 |
Loa Loa (eye worm) | glutathione reductase | 0.0757 | 0.383 | 0.5 |
Brugia malayi | glutathione reductase | 0.0757 | 0.383 | 1 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0833 | 0.4385 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (binding) | = 0.0708 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | 63.0957 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.